Morgan Stanley Maintains Equal-Weight on CME Gr, Raises Price Target to $233
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Mike Cyprys maintains an Equal-Weight rating on CME Group (NASDAQ:CME) and raises the price target from $210 to $233.
October 17, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on CME Group and increased the price target from $210 to $233, indicating a positive outlook.
The increase in price target from $210 to $233 by Morgan Stanley suggests a positive outlook for CME Group, which could lead to a short-term increase in stock price. The maintained Equal-Weight rating indicates a balanced view, but the raised target price is a positive signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100